The potential of HIV-1 nanotherapeutics: From in vitro studies to clinical trials

Nanomedicine

Volumn 10, Issue 24, 2015, Pages 3597-3609

  Roy, Upal ^a   Rodríguez, Jesse ^b   Barber, Paul ^a   Das Neves, José ^c,d   Sarmento, Bruno ^c,d   Nair, Madhavan ^a  

^a FLORIDA INTERNATIONAL UNIVERSITY   (United States)

^b WILLIAMS COLLEGE   (United States)

^c UNIVERSITY OF PORTO   (Portugal)

^d INSTITUTO DE INVESTIGAÇÃO E FORMAÇÃO AVANÇADA EM CIÊNCIAS E TECNOLOGIAS DA SAÚDE   (Portugal)

Author keywords

AIDS; cART; HIV; nanomedicine; nanoparticles

Indexed keywords

ANTI HUMAN IMMUNODEFICIENCY VIRUS AGENT; ASTODRIMER; CABOTEGRAVIR; DAPIVIRINE; DENDRIMER; EFAVIRENZ; ENFUVIRTIDE; ETRAVIRINE; HUMAN IMMUNODEFICIENCY VIRUS VACCINE; LIPOSOME; MARAVIROC; MC 1220; MICROBICIDE; NANOCARRIER; NANOMATERIAL; NANOSUSPENSION; POLYCAPROLACTONE; RALTEGRAVIR; RILPIVIRINE; SOLID LIPID NANOPARTICLE; TENOFOVIR; TMC 278LA; ULTRASMALL SUPERPARAMAGNETIC IRON OXIDE; UNCLASSIFIED DRUG; ZIDOVUDINE; POLYLYSINE;

ANTIVIRAL THERAPY; CLINICAL TRIAL (TOPIC); COMBINATION ANTIRETROVIRAL THERAPY; CONTROLLED DRUG RELEASE; DRUG BIOAVAILABILITY; DRUG DELIVERY SYSTEM; DRUG STRUCTURE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1 INFECTION; IN VITRO STUDY; INFECTION PREVENTION; MICELLE; NANOENCAPSULATION; NANOMEDICINE; PREVENTIVE HEALTH SERVICE; PRIORITY JOURNAL; REVIEW; SEXUAL TRANSMISSION; CHEMISTRY; DRUG EFFECTS; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HIV INFECTIONS; HUMAN IMMUNODEFICIENCY VIRUS 1; VIROLOGY;

ANTI-HIV AGENTS; ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE; CLINICAL TRIALS AS TOPIC; DENDRIMERS; HIV INFECTIONS; HIV-1; HUMANS; NANOMEDICINE; NANOSTRUCTURES; POLYLYSINE;

EID: 84949654506     PISSN: 17435889     EISSN: 17486963     Source Type: Journal    
DOI: 10.2217/nnm.15.160     Document Type: Review

References (81)

1. Gallo RC, Montagnier L. The discovery of HIV as the cause of AIDS. N. Engl. J. Med. 349(24), 2283-2285 (2003).
2. Joint United Nations Programme on HIV/AIDS (UNAIDS).
3. Fast-track: ending the AIDS epidemic by 2030. Geneva: UNAIDS (2014).
4. www.unaids.org 3 Joint United Nations Programme on HIV/AIDS (UNAIDS).
5. The gap report. Geneva: UNAIDS. (2014).
6. Mamo T, Moseman EA, Kolishetti N et al. Emerging nanotechnology approaches for HIV/AIDS treatment and prevention. Nanomedicine (Lond.) 5(2), 269-285 (2010).
7. Schooley RT. Longer-term immunologic effects and side effects of successful antiretroviral therapy. Clin. Infect. Dis. 29(1), 12-18 (1999).
8. Nolan D, Reiss P, Mallal S. Adverse effects of antiretroviral therapy for HIV infection: a review of selected topics. Expert Opin. Drug Safety 4(2), 201-218 (2005).
9. Lisziewicz J, Toke ER. Nanomedicine applications towards the cure of HIV. Nanomedicine (Lond.) 9(1), 28-38 (2013).
10. Fletcher CV, Staskus K, Wietgrefe SW et al. Persistent HIV-1 replication is associated with lower antiretroviral drug concentrations in lymphatic tissues. Proc. Natl Acad. Sci. USA 111(6), 2307-2312 (2014).
11. ClinicalTrials Database: NCT02165202. https://clinicaltrials.gov/ct2/show/NCT02165202
12. ClinicalTrials Database: NCT02076178. https://clinicaltrials.gov/ct2/show/NCT02076178
13. Fiandra L, Colombo M, Mazzucchelli S et al. Nanoformulation of antiretroviral drugs enhances their penetration across the blood brain barrier in mice. Nanomedicine (Lond.) 11(6), 1387-1397 (2015).
14. Rodriguez B, Asmuth DM, Matining RM et al. Safety, tolerability, and immunogenicity of repeated doses of dermavir, a candidate therapeutic HIV vaccine, in HIVinfected patients receiving combination antiretroviral therapy: results of the ACTG 5176 trial. J. Acquir. Immune Defic. Syndr. 64(4), 351-359 (2013).
15. Dutta T, Agashe HB, Garg M, Balakrishnan P, Kabra M, Jain NK. Poly (propyleneimine) dendrimer based nanocontainers for targeting of efavirenz to human monocytes/macrophages in vitro. J. Drug Target. 15(1), 89-98 (2007).
16. Parboosing R, Maguire GE, Govender P, Kruger HG. Nanotechnology and the treatment of HIV infection. Viruses 4(4), 488-520 (2012).
17. Chiappetta DA, Hocht C, Taira C, Sosnik A. Efavirenzloaded polymeric micelles for pediatric anti-HIV pharmacotherapy with significantly higher oral bioavailability [corrected]. Nanomedicine (Lond.) 5(1), 11-23 (2010).
18. Dubey V, Mishra D, Nahar M, Jain V, Jain NK. Enhanced transdermal delivery of an anti-HIV agent via ethanolic liposomes. Nanomedicine (Lond.) 6(4), 590-596 (2010).
19. Arunkumar N, Deecaraman M, Rani C. Nanosuspension technology and its applications in drug delivery. Asian J. Pharm. 3(3), 168 (2009).
20. ClinicalTrials Database: NCT02178800. https://clinicaltrials.gov/ct2/show/NCT02178800
21. Spreen WR, Margolis DA, Pottage JC Jr. Long-acting injectable antiretrovirals for HIV treatment and prevention. Curr. Opin. HIV AIDS 8(6), 565-571 (2013).
22. Baert L, vanT Klooster G, Dries W et al. Development of a long-acting injectable formulation with nanoparticles of rilpivirine (TMC278) for HIV treatment. Eur. J. Pharm. Biopharm. 72(3), 502-508 (2009).
23. Doblecki-Lewis S, Cohen S, Liu A. Clinical treatment options infectious diseases: update on PrEP implementation, adherence, and advances in delivery. Curr. Treat. Options Infect. Dis. 7(2), 101-112 (2015).
24. Verloes R, vant Klooster G, Baert L et al. TMC278 long acting -a parenteral nanosuspension formulation that provides sustained clinically relevant plasma concentrations in HIV-negative volunteers. 17th International AIDS Conference. Mexico City, Mexico, 3-8 August 2008.
25. Roy U, Mcmillan J, Alnouti Y et al. Pharmacodynamic and antiretroviral activities of combination nanoformulated antiretrovirals in HIV-1-infected human peripheral blood lymphocyte-reconstituted mice. J. Infect. Dis. 206(10), 1577-1588 (2012).
26. Gautam N, Roy U, Balkundi S et al. Preclinical pharmacokinetics and tissue distribution of long-acting nanoformulated antiretroviral therapy. Antimicrob. Agents Chemother. 57(7), 3110-3120 (2013).
27. Williams J, Sayles HR, Meza JL et al. Long-acting parenteral nanoformulated antiretroviral therapy: interest and attitudes of HIV-infected patients. Nanomedicine (Lond.) 8(11), 1807-1813 (2013).
28. Rajoli RK, Back DJ, Rannard S et al. Physiologically based pharmacokinetic modelling to inform development of intramuscular long-acting nanoformulations for HIV. Clin. Pharmacokinet. 54(6), 639-650 (2015).
29. Truong WR, Schafer JJ, Short WR. Once-daily, single-tablet regimens for the treatment of HIV-1 infection. PT 40(1), 44-55 (2015).
30. ClinicalTrials Database: NCT02120352. https://clinicaltrials.gov/ct2/show/NCT02120352
31. ClinicalTrials Database: NCT01031589. https://clinicaltrials.gov/ct2/show/NCT01031589
32. ClinicalTrials Database: NCT01593046. https://clinicaltrials.gov/ct2/show/NCT01593046
33. ClinicalTrials Database: NCT01565850. https://clinicaltrials.gov/ct2/show/NCT01565850
34. Sax P, Brar I, Elion R et al. 48 week study of tenofovir alafenamide (TAF) vs. Tenofovir disoproxil fumarate (TDF), each in a singletablet regimen (STR) with elvitegravir, cobicistat, and emtricitabine [E/C/F/TAF vs. E/C/F/TDF] for initial HIV treatment. Abstract IV-1464d. Presented at: The 53rd Interscience Conference on Antimicrobial Agents and Chemotherapy. Denver, CO, USA, 10-13 September 2013.
35. Liu Y, Kitrinos K, Babusis D et al. Lack of tenofovir alafenamide (TAF) effect on primary osteoblasts in vitro at clinically relevant drug concentrations. Abstract H-664. Presented at: The 53rd Interscience Conference on Antimicrobial Agents and Chemotherapy. Denver, CO, USA, 10-13 September 2013.
36. Atripla (efavirenz/emtricitabine/tenofovir disoproxil fumarate) package insert. Bristol-Myers Squibb and Gilead Sciences, Foster City, California, USA (2013).
37. Cada DJ, Torres S, Levien TL, Baker DE. Elvitegravir/Cobicistat/Emtricitabine/Tenofovir disoproxil fumarate tablets. Hosp. Pharm. 48(1), 48-56 (2013).
38. Nathan B, Bayley J, Waters L, Post FA. Cobicistat: a novel pharmacoenhancer for co-formulation with hiv protease and integrase inhibitors. Infect. Dis. Ther. 2(2), 111-122 (2013).
39. Juday T, Correll T, Anene A, Broder MS, Ortendahl J, Bentley T. Cost-effectiveness of the once-daily efavirenz/emtricitabine/tenofovir tablet compared with the once-daily elvitegravir/cobicistat/emtricitabine/tenofovir tablet as firstline antiretroviral therapy in HIV-infected adults in the US. Clinicoecon. Outcomes Res. 5, 437-445 (2013).
40. Cohen CJ, Meyers JL, Davis KL. Association between daily antiretroviral pill burden and treatment adherence, hospitalisation risk, and other healthcare utilisation and costs in a US medicaid population with HIV. BMJ Open 3(8), doi:10.1136/bmjopen-2013-003028 (2013) (Epub ahead of print).
41. Gomes MJ, Neves J, Sarmento B. Nanoparticle-based drug delivery to improve the efficacy of antiretroviral therapy in the central nervous system. Int. J. Nanomedicine 9, 1757-1769 (2014).
42. Gray F, Adle-Biassette H, Chretien F, Lorin de la Grandmaison G, Force G, Keohane C. Neuropathology and neurodegeneration in human immunodeficiency virus infection. Pathogenesis of HIV-induced lesions of the brain, correlations with HIV-associated disorders and modifications according to treatments. Clin. Neuropathol. 20(4), 146-55 (2001).
43. Sagar V, Pilakka-Kanthikeel S, Pottathil R, Saxena SK, Nair M. Towards nanomedicines for neuroAIDS. Rev. Med. Virol. 24(2), 103-124 (2014).
44. das Neves J, Amiji MM, Bahia MF, Sarmento B. Nanotechnology-based systems for the treatment and prevention of HIV/AIDS. Adv. Drug Deliv. Rev. 62(4-5), 458-477 (2010).
45. Dash PK, Gendelman HE, Roy U et al. Long-acting nanoformulated antiretroviral therapy elicits potent antiretroviral and neuroprotective responses in HIV-1-infected humanized mice. AIDS 26(17), 2135-2144 (2012).
46. Narayanasamy P, Switzer BL, Britigan BE. Prolongedacting, multi-targeting gallium nanoparticles potently inhibit growth of both HIV and mycobacteria in coinfected human macrophages. Sci. Rep. 5, 8824 (2015).
47. Haynes BF. New approaches to HIV vaccine development. Curr. Opin. Immunol. 35, 39-47 (2015).
48. Rohan LC, Devlin B, Yang H. Microbicide dosage forms. Curr. Top. Microbiol. Immunol. 383, 27-54 (2014).
49. Mccarthy TD, Karellas P, Henderson SA et al. Dendrimers as drugs: discovery and preclinical and clinical development of dendrimer-based microbicides for HIV and STI prevention. Mol. Pharm. 2(4), 312-318 (2005).
50. Tyssen D, Henderson SA, Johnson A et al. Structure activity relationship of dendrimer microbicides with dual action antiviral activity. PLoS ONE 5(8), e12309 (2010).
51. Jiang YH, Emau P, Cairns JS et al. SPL7013 gel as a topical microbicide for prevention of vaginal transmission of SHIV89.6P in macaques. AIDS Res. Hum. Retroviruses 21(3), 207-213 (2005).
52. Patton DL, Cosgrove Sweeney YT, Mccarthy TD, Hillier SL. Preclinical safety and efficacy assessments of dendrimer-based (SPL7013) microbicide gel formulations in a nonhuman primate model. Antimicrob. Agents Chemother. 50(5), 1696-1700 (2006).
53. Mcgowan I, Gomez K, Bruder K et al. Phase 1 randomized trial of the vaginal safety and acceptability of SPL7013 gel (VivaGel) in sexually active young women (MTN-004). AIDS 25 8 1057-1064 2011).
54. Moscicki AB, Kaul R, Ma Y et al. Measurement of mucosal biomarkers in a Phase 1 trial of intravaginal 3% StarPharma LTD 7013 gel (VivaGel) to assess expanded safety. J. Acquir. Immune Defic. Syndr. 59(2), 134-140 (2012).
55. Jimnez JL, Pion M, Mata FJDL et al. Dendrimers as topical microbicides with activity against HIV. N. J. Chem. 36(2), 299-309 (2012).
56. Sepulveda-Crespo D, Gomez R, De La Mata FJ, Jimenez JL, Munoz-Fernandez MA. Polyanionic carbosilane dendrimer-conjugated antiviral drugs as efficient microbicides: recent trends and developments in HIV treatment/therapy. Nanomedicine (Lond.) 11(6), 1481-1498 (2015).
57. Sepulveda-Crespo D, Sanchez-Rodriguez J, Serramia MJ et al. Triple combination of carbosilane dendrimers, tenofovir and maraviroc as potential microbicide to prevent HIV-1 sexual transmission. Nanomedicine (Lond.) 10(6), 899-914 (2015).
58. Seplveda-Crespo D, Serrama MJ, Tager AM et al. Prevention vaginally of HIV-1 transmission in humanized BLT mice and mode of antiviral action of polyanionic carbosilane dendrimer G2-S16. Nanomedicine (Lond.) 11(6), 1299-308 (2015).
59. Das Neves J, Michiels J, Arin KK et al. Polymeric nanoparticles affect the intracellular delivery, antiretroviral activity and cytotoxicity of the microbicide drug candidate dapivirine. Pharm. Res. 29(6), 1468-1484 (2012).
60. das Neves J, Amiji M, Bahia MF, Sarmento B. Assessing the physical-chemical properties and stability of dapivirineloaded polymeric nanoparticles. Int. J. Pharm. 456(2), 307-314 (2013).
61. das Neves J, Rocha CM, Goncalves MP et al. Interactions of microbicide nanoparticles with a simulated vaginal fluid. Mol. Pharm. 9(11), 3347-3356 (2012).
62. Alukda D, Sturgis T, Youan BB. Formulation of tenofovirloaded functionalized solid lipid nanoparticles intended for HIV prevention. J. Pharm. Sci. 100(8), 3345-3356 (2011).
63. Zhang T, Sturgis TF, Youan BB. pH-responsive nanoparticles releasing tenofovir intended for the prevention of HIV transmission. Eur. J. Pharm. Biopharm. 79(3), 526-536 (2011).
64. Meng J, Zhang T, Agrahari V, Ezoulin MJ, Youan BB. Comparative biophysical properties of tenofovir-loaded, thiolated and nonthiolated chitosan nanoparticles intended for HIV prevention. Nanomedicine (Lond.) 9(11), 1595-1612 (2014).
65. das Neves J, Nunes R, Machado A, Sarmento B. Polymerbased nanocarriers for vaginal drug delivery. Adv. Drug Deliv. Rev. doi:10.1016/j.addr.2014.12.004 (2014) (Epub ahead of print).
66. das Neves J, Sarmento B. Precise engineering of dapivirineloaded nanoparticles for the development of anti-HIV vaginal microbicides. Acta Biomater.18, 77-87 (2015).
67. Date AA, Shibata A, Goede M et al. Development and evaluation of a thermosensitive vaginal gel containing raltegravir+efavirenz loaded nanoparticles for HIV prophylaxis. Antiviral. Res. 96(3), 430-436 (2012).
68. Kovarova M, Council OD, Date AA et al. Nanoformulations of rilpivirine for topical pericoital and systemic coitus-independent administration efficiently prevent HIV transmission. PLoS Pathog. 11(8), e1005075 (2015).
69. Caron M, Besson G, Etenna SL et al. Protective properties of non-nucleoside reverse transcriptase inhibitor (MC1220) incorporated into liposome against intravaginal challenge of Rhesus macaques with RT-SHIV. Virology. 405(1), 225-233 (2010).
70. Ham AS, Cost MR, Sassi AB, Dezzutti CS, Rohan LC. Targeted delivery of PSC-RANTES for HIV-1 prevention using biodegradable nanoparticles. Pharm. Res. 26(3), 502-511 (2009).
71. Ball C, Woodrow KA. Electrospun fibers for microbicide drug delivery. In:Drug Delivery and Development of Anti HIV Microbicides . das Neves J, Sarmento B (Eds.) Pan Stanford, Singapore, 459-507 ( 2014).
72. das Neves J, Arajo F, Andrade F, Amiji M, Bahia MF, Sarmento B. Biodistribution and pharmacokinetics of dapivirine-loaded nanoparticles after vaginal delivery in mice. Pharm. Res. 31(7), 1834-1845 (2014).
73. Blakney AK, Ball C, Krogstad EA, Woodrow KA. Electrospun fibers for vaginal anti-HIV drug delivery. Antiviral. Res. 100(Suppl.), S9-S16 (2013).
74. Ball C, Krogstad E, Chaowanachan T, Woodrow KA. Drugeluting fibers for HIV-1 inhibition and contraception. PLoS ONE 7(11), e49792 (2012).
75. Ball C, Woodrow KA. Electrospun solid dispersions of Maraviroc for rapid intravaginal preexposure prophylaxis of HIV. Antimicrob. Agents Chemother. 58(8), 4855-4865 (2014).
76. Krogstad EA, Woodrow KA. Manufacturing scale-up of electrospun poly(vinyl alcohol) fibers containing tenofovir for vaginal drug delivery. Int. J. Pharm. 475(1-2), 282-291 (2014).
77. Nunes R, Sarmento B, das Neves J. Formulation and delivery of anti-HIV rectal microbicides: advances and challenges. J. Control. Release 194, 278-294 (2014).
78. Sarmento B, das Neves J. Nanosystem formulations for rectal microbicides: a call for more research. Ther. Deliv. 3(1), 1-4 (2012).
79. das Neves J, Arajo F, Andrade F et al. In vitro and ex vivo evaluation of polymeric nanoparticles for vaginal and rectal delivery of the anti-HIV drug dapivirine. Mol.Pharm. 10(7), 2793-2807 (2013).
80. Parboosing R, Maguire GE, Govender P, Kruger HG. Nanotechnology and the treatment of HIV infection. Viruses 4(4), 488-520 (2012)
81. Gulick R. HIV treatment 2020: what will it look like? J. Int. AIDS Soc. 17(4 Suppl. 3), 19528 (2014).